secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2021-12-20T23:59:59+00:00
Accession:  0001193125-21-361760
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics terminates EVP R&D Tony W. Ho without cause
---------------------------------------------------------------

- Tony W. Ho terminated as Executive Vice President, Research and Development on December 14, 2021.
- Termination is without cause and not the result of any disagreement with the Company.
- No replacement has been announced; Samarth Kulkarni remains CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312521361760/0001193125-21-361760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312521361760/d274235d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-361760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer